Last $6.96 USD
Change Today +0.3499 / 5.29%
Volume 6.6K
INNL On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

innocoll ag-spon adr (INNL) Snapshot

Open
$6.97
Previous Close
$6.61
Day High
$7.00
Day Low
$6.61
52 Week High
07/25/14 - $9.51
52 Week Low
10/14/14 - $4.45
Market Cap
137.8M
Average Volume 10 Days
3.7K
EPS TTM
--
Shares Outstanding
19.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INNOCOLL AG-SPON ADR (INNL)

Related News

No related news articles were found.

innocoll ag-spon adr (INNL) Related Businessweek News

No Related Businessweek News Found

innocoll ag-spon adr (INNL) Details

Innocoll AG manufactures and sells collagen-based products for post-surgical applications primarily in Europe, the Middle East, and Asia. The company’s CollaGUARD, a transparent bioresorbable collagen film for the prevention of post-operative adhesions in various surgical applications, including digestive, colorectal, gynecological, and urological surgeries in open and laparoscopic approaches; Collatamp Gentamicin Surgical Implant for the treatment or prevention of post-operative infection; and Septocoll, a bioresorbable dual-action collagen sponge for the treatment or prevention of post-operative infection. Its lead product candidates that have completed Phase II trials comprise XaraColl, an implantable and bioresorbable collagen sponge for the treatment of post-operative pain; and Cogenzia, a topically applied bioresorbable collagen sponge for the treatment of diabetic foot infections. The company was formerly known as Innocoll GmbH and changed its name to Innocoll AG in July, 2014. Innocoll AG was incorporated in 1997 and is headquartered in Athlone, Ireland.

77 Employees
Last Reported Date: 07/24/14
Founded in 1997

innocoll ag-spon adr (INNL) Top Compensated Officers

Chief Financial Officer and Member of Managem...
Total Annual Compensation: $238.1K
Head of Portfolio Operations and Member of Ma...
Total Annual Compensation: $387.4K
Compensation as of Fiscal Year 2013.

innocoll ag-spon adr (INNL) Key Developments

Innocoll AG Announces Management Changes

Innocoll AG announced that Tony Zook, formerly executive vice president, Global Commercial Operations, at AstraZeneca, has been appointed chief executive officer effectively immediately. Michael Myers, will continue with the company as head of Portfolio Operations. The executive changes were made to better position the company as its pipeline advances to late-stage clinical development and prepares to become a fully-integrated specialty pharmaceutical company. Mr. Zook has extensive pharmaceutical executive management, commercialization and marketing experience. He held several executive positions at AstraZeneca including executive vice president of Global Commercial Operations from 2010 to 2013, president and chief executive officer of the North American division from 2007 to 2010 and president of Medimmune from 2008 to 2010.

Innocoll AG, Annual General Meeting, Dec 04, 2014

Innocoll AG, Annual General Meeting, Dec 04, 2014., at 14:00 Central European Standard Time. Location: The offices of Dr. Susanne Frank, Residenzstrae 27.

Innocoll AG Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Innocoll AG reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of EUR 1,141,000 compared to EUR 627,000 a year ago. This increase was primarily due to an increase in sales by Jazz Pharmaceuticals of CollatampG and Biomet 3i's launch of RegenePro, product to treat dental wounds in the US. Loss from operating activities –continuing operations was EUR 3,592,000 compared to EUR 1,480,000 a year ago. Profit before income tax was EUR 1,991,000 compared to EUR 13,042,000 a year ago. Profit attributable to equity holders of the company was EUR 1,970,000 compared to EUR 13,025,000 a year ago. Diluted earnings per share were EUR 1.40 compared to diluted loss per share of EUR 1.04 a year ago. Non-GAAP net earnings were EUR 286,000 compared to non-GAAP net losses of EUR 771,000 a year ago. For the nine months period, the company reported revenue of EUR 3,742,000 compared to EUR 2,712,000 a year ago. Loss from operating activities –continuing operations was EUR 9,730,000 compared to EUR 4,408,000 a year ago. Loss before income tax was EUR 16,322,000 compared to profit before income tax of EUR 6,743,000 a year ago. Loss attributable to equity holders of the company was EUR 16,429,000 compared to profit attributable to equity holders of the company of EUR 6,690,000 a year ago. Diluted loss per share was EUR 33.36 compared to EUR 6.00 a year ago. Non-GAAP net losses were EUR 7,237,000 compared to EUR 4,445,000 a year ago. Net cash used in operating activities was EUR 7,078,000 compared to EUR 1,796,000 a year ago. Purchases of property, plant and equipment were EUR 598,000 compared to EUR 222,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INNL:US $6.96 USD +0.3499

INNL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $74.56 USD +0.11
Durect Corp $0.80 USD -0.0133
Sanofi €75.50 EUR +0.51
View Industry Companies
 

Industry Analysis

INNL

Industry Average

Valuation INNL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.0x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INNOCOLL AG-SPON ADR, please visit www.innocollinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.